Catabolism of lipoproteins and metabolic syndrome

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 4, 2009, Pages 366-371

  Therond, Patrice ^a,b  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Catabolism; Drugs; HDL; Insulin; LDL; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEALTH CARE ORGANIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID OXIDATION; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, VLDL; METABOLIC SYNDROME X; RISK FACTORS; TRIGLYCERIDES;

EID: 68049109461     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32832c5a12     Document Type: Review

References (29)

1. Adiels M, Olofsson S-O, Taskinen M-R, Boren J. Overproduction of very lowdensity lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:1225-1236. A general review describing the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome.
2. Kahn R. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2005; 28:2289-2304.
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
4. Alberti KG, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
5. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
6. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062.
7. Bergman RN, Kim SP, Hsu IR, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007; 120:S3-S8.
8. Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003; 46:733-749.
9. Adiels M, Westerbacka J, Soro-Paavonen, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007; 50:2356-2365.
10. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. the metabolic syndrome, LDL particle size, and atherosclerosis. The Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000; 20:2140-2147.
11. Georgieva AM, van Greevenbroek MM, Krauss RM, et al. Subclasses of lowdensity lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004; 24:744-749.
12. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31:429-439.
13. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistance, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003; 36:421-429.
14. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89:4963-4971.
15. Kontush A, De Faria EC, Chantepie S, Chapman MJ. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004; 24:526-533.
16. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 2 and 3. J Lipid Res 2000; 41:1495-1508.
17. Ji J, Watts GF, Johnson AG, et al. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 2006; 91:973-979.
18. Brown WV, Clark L, Falko JM, et al. Optimal management of lipids in diabetes and metabolic syndrome. J Clin Lipidol 2008; 2:335-342. A general review on the management of dyslipidemia and increased atherosclerotic risk in metabolic syndrome with effects of treatments.
19. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811-822. In this article, a panel of experts developed a consensus position, addressing questions in relation with lipid management.
20. Holvoet P, Lee D-H, Steffes M, et al. Association between circulating oxidized low density lipoprotein and incidence of the metabolic syndrome. JAMA 2008; 299:2287-2293. This study shows that oxidized circulating LDL was associated with increased incidence of metabolic syndrome, as well as its components of abdominal obesity, hyperglycemia and hypertriglyceridemia.
21. Ooi EM, Watts GF, Nestel PJ, et al. Dose-dependent regulation of highdensity lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 2008; 93:430-437. This study describes the mechanism of action of rosuvastatin for its HDL-raising effect in the metabolic syndrome.
22. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368:919-928.
23. Steiner G. Fenofibrate for cardiovascular disease prevention I metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol 2008; 102:28L-33L.
24. Rosenson RS, Huskin AL, Wolff DA, et al. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008; 198:381-388.
25. Barter P, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28:39-46. This review concludes that fibrates could be used in combination with statins to reduce the cardiovascular risk in overweight people with high triglyceride and low HDL-C levels.
26. Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav 2008; 94:187-197.
27. Verges B. Clinical interests of PPARs ligands. Diabetes Metab 2004; 30:7-12.
28. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006; 48:1774-1781.
29. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.